argenx SE ADR
ARGX: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$772.00 | Chvf | Tmybjknh |
Argenx Is Building a Moat as Vyvgart's Efficacy Extends Across Autoimmune Diseases
Business Strategy and Outlook
Dutch biotech Argenx aims to build a portfolio of autoimmune treatments around Vyvgart, which received Food and Drug Administration approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak sales of more than $15 billion if approvals can extend into new autoimmune indications in neurology, hematology, dermatology, and nephrology over the next several years, although competitors in testing and uncertainty around future clinical trial results for Vyvgart prevent us from assigning the firm an economic moat.